4 days ago
TEVA
AnalystsJason GerberryJason Gerberry's Stock Forecasts
AnalystsJason Gerberry
Analyst Ranking
Top 20%
#881 out of 4595 analysts
Average Return
+5.17%
Win Rate
48%40 out of 83
Risk vs Reward
Poor
Good
Jason Gerberry's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Horizon Therapeutics Public Ltd CoHZNP | +246.56% | $24.87 | $86.19 | 2020-03-23 - 2021-03-23 | Strong Buy |
Bioverativ IncBIVV | +134.78% | $44.10 | $103.54 | 2017-02-15 - 2018-02-15 | Buy |
Teva Pharmaceutical Industries LtdTEVA | +97.93% | $8.21 | $16.25 | 2023-05-11 - 2024-05-10 | Strong Buy |
Jazz Pharmaceuticals PLCJAZZ | +87.27% | $87.74 | $164.31 | 2020-03-23 - 2021-03-23 | Strong Buy |
Beyondspring IncBYSI | +87.16% | $4.44 | $0.57 | 2021-12-02 - 2022-12-01 | Sell |
Jason Gerberry Analyst Color
Get additional color on Jason Gerberry's coverage of popular stocks
5 months ago
ARWR
5 months ago
PCVX
5 months ago
XENE
5 months ago
BLUE
5 months ago
IMVT
6 months ago
BLUE
9 months ago
LYRA
9 months ago
TEVA
10 months ago
JAZZ
10 months ago
BLUE
a year ago
IMVT
a year ago
ACLX
a year ago
PCVX
a year ago
FGEN
2 years ago
XENE
2 years ago
KRTX
Jason Gerberry's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Teva Pharmaceutical Industries LtdTEVA | 8 | Strong Buy | $21.00 | +24.04% | Maintains | 4 days ago |
Prokidney CorpPROK | 2 | Hold | $4.00 | +14.94% | Maintains | 5 days ago |
Intra Cellular Therapies IncITCI | 1 | Strong Buy | $91.00 | +35.34% | Maintains | 2 months ago |
Galapagos NvGLPG | 5 | Sell | $31.00 | +11.43% | Downgrades | 2 months ago |
Lyra Therapeutics IncLYRA | 3 | Strong Buy | $11.00 | +3,253.66% | Maintains | 2 months ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Strong Buy | $23.00 | +42.24% | Initiates Coverage On | 3 months ago |
Alkermes PLCALKS | 5 | Hold | $29.00 | +23.93% | Maintains | 5 months ago |
Arrowhead Pharmaceuticals IncARWR | 2 | Strong Buy | $37.00 | +61.22% | Maintains | 5 months ago |
Vaxcyte IncPCVX | 2 | Strong Buy | $80.00 | +13.85% | Maintains | 5 months ago |
Xenon Pharmaceuticals IncXENE | 2 | Strong Buy | $56.00 | +47.10% | Maintains | 5 months ago |
Ionis Pharmaceuticals IncIONS | 3 | Strong Buy | $62.00 | +65.03% | Upgrades | 5 months ago |
Harmony Biosciences Holdings IncHRMY | 2 | Sell | $30.00 | +2.04% | Downgrades | 5 months ago |
Bluebird Bio IncBLUE | 6 | Strong Buy | $5.00 | +453.71% | Maintains | 5 months ago |
Immunovant IncIMVT | 3 | Strong Buy | $51.00 | +100.87% | Maintains | 5 months ago |
Amphastar Pharmaceuticals IncAMPH | 1 | Hold | $63.00 | +48.83% | Initiates Coverage On | 7 months ago |
Viatris IncVTRS | 2 | Sell | $9.00 | -15.09% | Downgrades | 7 months ago |
Karuna Therapeutics IncKRTX | 2 | Strong Buy | $259.00 | -21.47% | Maintains | 9 months ago |
Oculis Holding AgOCS | 2 | Strong Buy | $24.00 | +104.08% | Maintains | 9 months ago |
Jazz Pharmaceuticals PLCJAZZ | 3 | Strong Buy | $217.00 | +106.18% | Maintains | 10 months ago |
Fibrogen IncFGEN | 6 | Sell | $2.00 | +66.67% | Downgrades | 10 months ago |
Axsome Therapeutics IncAXSM | 2 | Hold | $81.00 | +10.31% | Upgrades | 10 months ago |
Cara Therapeutics IncCARA | 2 | Sell | $4.00 | N/A | Maintains | a year ago |
Arcellx IncACLX | 3 | Strong Buy | $50.00 | N/A | Maintains | a year ago |
Applied Molecular Transport IncAMTI | 2 | Sell | $0.50 | N/A | Downgrades | a year ago |
Allogene Therapeutics IncALLO | 1 | Sell | $9.00 | N/A | Downgrades | a year ago |
Organon & CoOGN | 3 | Sell | $25.00 | N/A | Downgrades | 2 years ago |
Mirati Therapeutics IncMRTX | 3 | Hold | $141.00 | N/A | Upgrades | 2 years ago |
Beyondspring IncBYSI | 2 | Sell | $5.00 | N/A | Downgrades | 3 years ago |
Dice Therapeutics IncDICE | 1 | Strong Buy | $41.00 | N/A | Initiates Coverage On | 3 years ago |
Finch Therapeutics Group IncFNCH | 1 | Strong Buy | $750.00 | N/A | Initiates Coverage On | 3 years ago |
Bausch Health Companies IncBHC | 2 | Sell | $27.00 | N/A | Downgrades | 3 years ago |
Aerie Pharmaceuticals IncAERI | 2 | Sell | $9.00 | N/A | Downgrades | 4 years ago |
Coherus Biosciences IncCHRS | 1 | Hold | $20.00 | N/A | Initiates Coverage On | 4 years ago |
Verrica Pharmaceuticals IncVRCA | 1 | Hold | $10.00 | N/A | Downgrades | 4 years ago |
Global Blood Therapeutics IncGBT | 1 | Strong Buy | $92.00 | N/A | Initiates Coverage On | 4 years ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $180.00 | N/A | Maintains | 4 years ago |
Arena Pharmaceuticals IncARNA | 1 | Strong Buy | $56.00 | N/A | Upgrades | 4 years ago |
Horizon Therapeutics Public Ltd CoHZNP | 1 | Strong Buy | $42.00 | N/A | Maintains | 4 years ago |
Pfizer IncPFE | 2 | Strong Buy | $48.00 | N/A | Maintains | 5 years ago |
Bristol Myers Squibb CoBMY | 4 | Hold | $51.00 | N/A | Maintains | 5 years ago |
Foamix Pharmaceuticals LtdFOMX | 1 | Strong Buy | $11.00 | N/A | Initiates Coverage On | 5 years ago |
Abbvie IncABBV | 3 | Strong Buy | $106.00 | N/A | Maintains | 6 years ago |
Nabriva Therapeutics PLCNBRVF | 2 | Strong Buy | $1,250.00 | N/A | Maintains | 6 years ago |
Merck & Co IncMRK | 3 | Strong Buy | $74.00 | N/A | Maintains | 6 years ago |
Allergan PLCAGN | 3 | Strong Buy | $213.00 | N/A | Maintains | 6 years ago |
Momenta Pharmaceuticals IncMNTA | 1 | Hold | N/A | N/A | Downgrades | 7 years ago |
Bioverativ IncBIVV | 1 | Buy | $56.00 | N/A | Initiates Coverage On | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.